Core Insights - Autonomix Medical, Inc. has reported long-term data indicating a nearly 66% reduction in pain for patients with severe pancreatic cancer pain, with a mean reduction of 5.08 on the VAS pain scale [1][7] - 100% of responders were opioid-free at the 3-month follow-up, highlighting the potential of the technology as a non-opioid alternative for pain management [2][7] - The company is expanding its proof-of-concept studies to include additional visceral cancers, indicating a broader market opportunity [3][4] Group 1: Study Results - The PoC 1 study demonstrated statistically significant pain relief as early as 24 hours post-procedure, with sustained relief lasting up to five months [3][9] - Responding patients reported a mean 76.5% improvement in global health and a 51.5% improvement in functional ability at 7 days post-procedure [7][9] - The study enrolled 20 patients, with 19 treated successfully, and showed a strong safety profile with no serious adverse events related to the procedure [11][9] Group 2: Technology and Market Potential - Autonomix's technology is a platform that could address various indications, including cardiology and chronic pain management, beyond just cancer pain [4][12] - The follow-on PoC 2 phase aims to evaluate pain management for additional visceral cancers, expanding the potential addressable market significantly [3][4] - The company's catheter-based microchip sensing array technology is designed to detect and differentiate neural signals, which may enhance treatment efficacy [10][12]